Assess the Safety and Tolerability of SNS851 in Healthy Participants
ConditionMetabolic Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorOneness Biotech Co., Ltd.
About this trial
This is a Phase I, randomized, double-blind study designed to evaluate the safety, tolerability and pharmacokinetics of subcutaneous administration of SNS851 in healthy participants.
Eligibility criteria
Qualifiers
Able to provide written informed consent. Willing, committed, and able to return for all clinic visits and complete all protocol specified procedures.
Healthy male or female, aged between 18 and 55 years, inclusive at screening.
Body mass index (BMI) of greater than or equal to 18 kg/m2 and lesser than or equal to 32 kg/m2 at Screening.
Negative human immunodeficiency virus, viral hepatitis B and C serology at Screening.
Disqualifiers
Weight loss of more than 10% within the last 3 months prior to screening.
Has any clinical safety laboratory result considered clinically significant by the Investigator (or designee)
In the opinion of the PI (or designee), has evidence of other forms of known chronic liver disease
Participants with history or pre-existing renal disease
Trial design
Treatments tested in this trial
- SNS851
- Placebo
Treatment groups
52 Participants
are divided into 2 treatment groupsLocations
1Veritus Research Melbourne Australia
Sponsors and collaborators
Oneness Biotech Co., Ltd.
Lead sponsor
Source ClinicalTrials.gov